ABOS
Acumen·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 1
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ABOS
Acumen Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company that developing novel targeted therapeutics for Alzheimer's disease
1210-1220 Washington St.
Suite 210
Newton
Massachusetts 02465
Develops Alzheimer's disease disease-modifying treatments.
Acumen Pharmaceuticals, Inc., was incorporated in Delaware in 1996. The company is a clinical-stage biopharmaceutical company that is developing a new disease-modifying approach to target what the company believes is a key root cause of Alzheimer's disease, or AD. Alzheimer's disease is a progressive neurodegenerative disease of the brain that causes loss of memory and cognitive function, and ultimately death.
Company Financials
EPS
ABOS has released its 2026 Q2 earnings. EPS was reported at -0.45, versus the expected -0.36, missing expectations. The chart below visualizes how ABOS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
